Semaglutide shows an unexpected respiratory signal in asthma and COPD
Semaglutide, the GLP-1 receptor agonist sold as Ozempic and Wegovy, was associated with fewer acute respiratory attacks in a large real-world analysis presented at the European Respiratory Society Congress in Barcelona. In people with asthma, use of semaglutide appeared to align with nearly a 40% reduction in asthma attacks. In COPD, the same drug was linked to about a 20% reduction in flare-ups.
Those findings are not what clinicians usually expect from a medicine best known for lowering glucose and driving weight loss. Yet they fit a growing biological argument that metabolic therapies may influence the airways through pathways that extend beyond body weight alone. GLP-1 receptor agonists have been linked in prior work to anti-inflammatory effects, and chronic airway disease often coexists with obesity, insulin resistance, and broader metabolic dysfunction. In that setting, a medication that improves systemic inflammation and metabolic stress could plausibly alter the frequency or severity of respiratory exacerbations.
The study was led by Professor Chloe Bloom of Imperial College London and presented by Dr. Bohee Lee. Investigators asked a straightforward but clinically important question: do people with asthma or COPD who start a GLP-1 receptor agonist experience fewer acute attacks than similar patients treated with a different diabetes drug? To answer it, they used UK electronic health records and carried out four parallel studies, each involving between 20,000 and 22,000 people who had begun treatment with either a GLP-1 medication or a sulfonylurea.
The scale matters because respiratory exacerbations are common, costly, and often triggered by the same cardiometabolic factors that drive diabetes and obesity. A reduction in attacks, if confirmed, could reshape how clinicians think about comorbidity management in patients who already qualify for GLP-1 therapy for metabolic reasons.
Why semaglutide stood out among GLP-1 therapies
Among the GLP-1 drugs examined, semaglutide showed the strongest association with benefit, especially in asthma. The drug’s signal reached the level of nearly 40% fewer asthma attacks, while COPD flare-ups fell by about 20% in the semaglutide-treated group. In practical terms, this suggests the effect may not be a class-wide blur measured only by weight loss or glycemic improvement; individual agents may differ in how they relate to respiratory outcomes.
The observation invites mechanistic speculation, but it should stay anchored to the data. Semaglutide may be acting through a combination of anti-inflammatory activity, reduced obesity-related mechanical burden on the chest wall, and better metabolic control that lowers systemic stress on the airways. None of those pathways has yet been proven as the dominant explanation in asthma or COPD, and none can substitute for a randomized trial. Still, the fact that both asthma and COPD moved in the same direction raises the possibility that airway biology is sensitive to metabolic signaling in ways that routine pulmonary care has not fully captured.
One sentence captures the central clinical tension: the signal is real enough to matter, but not yet strong enough to change prescribing by itself.
Bloom stressed that the results should not be used to start GLP-1 receptor agonists specifically for asthma or COPD outside existing prescribing guidance. People with airway disease should not be placed on these drugs solely for lung benefit until clinical trials confirm the association and define which patients, if any, are most likely to benefit. The current findings are encouraging, but they remain observational and therefore vulnerable to confounding, treatment-selection effects, and differences between patients who receive GLP-1 therapy and those who do not.
Metabolic health is moving into respiratory medicine
The study drew commentary from Dr. Alexander Mathioudakis of the European Respiratory Society, who was not involved in the research. He described obesity and metabolic dysfunction as common in airways disease and often under-recognized as problems that should be addressed directly. He also called the work one of the largest real-world studies to examine GLP-1 receptor agonists and airways disease, and one of the first to ask whether individual GLP-1 agents differ in their respiratory effects.
That perspective is clinically important because asthma and COPD are not isolated lung disorders in many adults. Exacerbation risk is shaped by obesity, insulin resistance, deconditioning, systemic inflammation, and medication burden. If metabolic therapy alters those drivers, the effect could surface first as fewer attacks rather than as dramatic improvements in lung function. Patients may feel fewer urgent symptom escalations before any spirometry shift becomes obvious.
The call for future research is more specific than a generic request for “more data.” Trials should include respiratory endpoints from the start: asthma attacks, COPD exacerbations, lung function, symptom burden, and quality of life. Without those outcomes, a therapy designed for diabetes or obesity can easily appear invisible to pulmonology even if it exerts a meaningful downstream effect on the airways.
A second practical point follows from the design itself. This analysis used real-world records rather than a randomized treatment allocation, so it can identify associations but cannot prove causality. Patients receiving GLP-1 receptor agonists may differ in unmeasured ways from those treated with sulfonylureas, and those differences could influence respiratory risk. The size of the cohort strengthens the signal, but it does not erase the need for trial-level confirmation.
For now, semaglutide’s respiratory association is best viewed as a hypothesis-generating finding with immediate relevance for research design and cautious relevance for bedside thinking. Clinicians managing asthma or COPD in patients with obesity or type 2 diabetes may now have a stronger reason to consider that metabolic treatment choices could intersect with airway outcomes. The next step has to be prospective testing, because only a randomized trial can show whether the fewer attacks seen here reflect a true drug effect rather than the pattern of who received the drug in routine care.